Project Grant R00HL169827
Award Date
7/15/25
Completion Date
6/30/28
Dollars Obligated
$248K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Shreveport, LA 71103, USA
Similar Awards
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,245,515.38 to The Methodist Hospital Research Institute (HMRI) to investigate the role of cell metabolism and epigenetic regulation in transdifferentiation and vascular regeneration. The research aims to determine how inflammatory signaling and metabolic shifts can facilitate the transformation of fibroblasts into endothelial cells,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $528,179 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Miami. The grant supports research to investigate whether extracellular vesicles mediate the systemic effects of ischemia training on monocyte reprogramming, and to determine if regulation of the DHCR24 enzyme in myeloid cells impacts limb perfusion, function, and arteriogenesis in peripheral arterial disease. The research...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $802,762 to The University of Texas Southwestern Medical Center to investigate the genetic mechanisms underlying congenital heart disease (CHD). The key objectives are to: 1) Define the transcription factors and gene regulatory networks controlling human cardiac development; 2) Identify and characterize genetic variants regulating cardiac gene programs; and 3)...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $321,848 to The Trustees of the University of Pennsylvania to conduct research on the role of hemodynamic forces and transcription factors KLF2 and KLF4 in regulating myxomatous valve disease pathogenesis. The research aims to characterize the impact of hemodynamic forces on valve homeostasis, identify specific targets of valve...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $291,848 to Tulane University to evaluate the impact of loss of heterozygosity on localized arteriovenous malformation (AVM) formation in hereditary hemorrhagic telangiectasia (HHT). The research aims to develop an HHT mouse model of SMAD4 loss of heterozygosity, compare it to previous SMAD4 knockout models, and explore the role of localized loss of function...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the development of a lesion-targeted nanotherapeutic to address vascular smooth muscle cell (VSMC) dysfunction and mitigate neointimal hyperplasia (NIH), which is a significant issue arising from vascular damage during interventions. The project aims to integrate in vitro transcribed CARMN RNA (a long non-coding RNA critical...
This $147,486 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the mechanistic relationship between bicuspid aortic valve (BAV)-induced mechanical stress and the development of premature calcific aortic stenosis. The research project, conducted by the Medical College of Wisconsin, Inc., aims to: 1) Delineate the BAV-specific mechanosensitive signaling pathway between vascular endothelial cells...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $559,893 to the University of Tennessee Health Science Center (UTHSC) to investigate the role of the RSPO2-LGR4 signaling pathway in regulating arterial lymphangiogenesis, vascular smooth muscle cell (VSMC) phenotypic changes, and atherosclerosis development. The project aims to determine the functional impact of VSMC-derived RSPO2 on...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $381,250 to Clemson University to conduct research aimed at identifying novel atheroprotective mechanisms. The goal is to test whether the expression of ABC-transporters ABCA1 and ABCG1 in vascular smooth muscle cells is atheroprotective and could represent a novel strategy for treating atherosclerosis. The project will utilize...
This Project Grant award of $788,513 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research focused on understanding the mechanisms underlying the maintenance of cardiac chamber identity in zebrafish. The research aims to elucidate the genetic pathways and signaling mechanisms that reinforce ventricular cardiomyocyte identity and suppress the transition to an atrial identity. Key objectives include identifying the downstream...